Centogene N.V. Stock News

CENTOGENE's rare disease mutation database offers new features and previously unpublished variants CENTOGENE's rare disease mutation database offers new features and previously unpublished variants

Research leads to diagnosis and treatment options for rare disease patients Research leads to diagnosis and treatment options for rare disease patients

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Centogene N.V. (CNTG) CEO Andrin Oswald on Q4 2020 Results - Earnings Call Transcript

Delivers very strong financial results in unprecedented year Delivers very strong financial results in unprecedented year

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clin

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clini

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis

Seeking Alpha Transcripts | Healthcare Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript Dec. 16, 2020 2:58 PM ET | | About: Centogene N.V. (CNTG) by: SA Transcript

Shares of Centogene (NASDAQ:CNTG) remained unaffected in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 97.88% year over year to ($0.30), which

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clini

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transfo

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnership Provi